
NIAID *Candida auris* Workshop Highlights & Funding Opportunities on Clinical Research

Baoying Liu, Ph.D

Bacteriology and Mycology Branch

Division of Microbiology and Infectious Diseases

NIAID, NIH, HHS

August 4, 2020



Understanding the biology, antifungal resistance and clinical implications of *Candida auris*

January 28-29, 2020
NIAID Conference Center
5601 Fishers Lane, 1D13

For information and registration:
<https://www.cvent.com/d/17qlqs>

There is no fee to attend this conference, however, registration is required.

The views expressed in written conference materials or publications and by speakers and moderators at HHS-sponsored conferences do not necessarily reflect the official policies of the Department of Health and Human Services (HHS), nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.



Workshop Objectives

- Bring together a diverse group of stakeholders (researchers, clinicians, industry, intramural NIAID, CDC, and FDA).
- Determine what is known about this organism, what are the most serious knowledge gaps.
- Discuss how to best leverage resources to combat this unique fungal pathogen.



Agenda Topics

- Emergence and unique features of the MDR fungal pathogen
- Epidemiological and Clinical Characteristics
- Diagnostics and decolonization
- Resistance, immune recognition and novel therapeutics
- Therapeutics in the pipeline
- Breakout session to capture feedback

Takeaways from the Breakout Session

- Access to clinical isolates
 - Sequence data

<https://wwwn.cdc.gov/arisolatebank/Panel/PanelDetail?ID=2>

CDC & FDA Antibiotic Resistance Isolate Bank



- Decolonization
- Special considerations for resource limited settings
- Clinical studies and trials

<https://www.cvent.com/d/17qlqs>



National Institute of
Allergy and
Infectious Diseases

NIAID Conferences

NIAID Funding Opportunities on Clinical Research



- Investigator-initiated Clinical Trial Awards
 - NIH Research Project Grant (Parent R01, Clinical Trial required)
 - NIH Exploratory/developmental Research Grant (R21, CT required)
 - NIAID Clinical Trial Implementation Corporative Agreement (U01, CT required)
- NIAID Clinical Trial Planning Grant (R34, Clinical Trial Not allowed)
- Small Business Grant– NIAID SBIR Clinical Trial Implementation Corporative Agreement (U44, Clinical Trial required)
- Phase I Clinical Trial Units for Therapeutics (Support Phase I Clinical Trial)
<https://www.niaid.nih.gov/research/phase-i-clinical-trial-units>

Examples of Current Grant Opportunities

- NIAID Clinical Trial Implementation Corporative Agreement
 - U01 (PAR-18-633)
 - Open until 2021
 - Support high risk clinical trials
 - Maximum period is 5 years
 - Prior consultation is required if the budget \geq 500K direct cost/year
- NIAID SBIR Clinical Trial Implementation Corporative Agreement
 - U44 (PA-18-632)
 - Open until 2021
 - NIAID: up to \$1M/year for up to 3 years with waiver for approved topics & budget justification
 - Fast Track; Phase II, Phase IIB Competing Renewal (Phase IIB)



Thank you

- For updates on **Funding Opportunities**, subscribe to **NIAID Funding News**
<https://www.niaid.nih.gov/grants-contracts/funding-news>
- **NIAID Council-cleared Concepts** – upcoming potential opportunities
<https://www.niaid.nih.gov/grants-contracts/potential-opportunities>

Contact Information:

Baoying Liu

Baoying.Liu@nih.gov

Text/Call: 240-762-8796